Advertisement
Table 4 Availability of interventions for PPH treatment bundle: % (95% CI)
| Phase 1 (n = 69) | Phase 2 (n = 69) | p-value | |
|---|---|---|---|
| Step 1: Misoprostol – treatment doses | |||
| Received at least 1 procurement of misoprostol treatment doses | 72.8 (55.5, 91.2) | 75.3 (52.1, 89.5) | P = .78 |
| Experienced stock out within the last 12 months | 24.7 (9.4, 50.8) | 53.4 (33.1, 72.6) | P = .06 |
| Stock-out levels within last 12 months | |||
| Never | 75.3 (49.2, 90.6) | 47.2 (27.7, 67.7) | P = .07 |
| Less than 1 month | 5.4 (1.5, 17.2) | 26.6 (12.0, 49.2) | |
| 1–3 months | 10.4 (2.6, 33.1) | 26.1 (10.6, 51.3) | |
| Over 3 months | 8.9 (1.2, 44.1) | 0 | |
| Expired stock at time of data collection | 25.2 (11.9, 45.9) | 49.8 (33.3, 66.4) | P = .05 |
| Step 2: Uterine balloon tamponade kits | |||
| Received at least 1 procurement of UBT kits | 80 (61.5, 91.0) | 80 (57.0, 92.0) | p = .63 |
| Experienced stock-out within the last 12 months | 0.3 (0, 2.7) | 23.4 (10.1, 45.4) | p < .001 |
| Stock-out levels within last 12 months | |||
| Never | 99.7 (97.3, 100) | 81.8 (59.4, 93.2) | p = .001 |
| Less than 1 month | 0 | 2.1 (0.4, 9.3) | |
| 1–3 months | 0.3 (0, 2.7) | 16.1 (5.3, 39.9) | |
| Over 3 months | 0 | 0 | |
| Incomplete UBT kits in stock | 9.6 (3.8, 22.3) | 60.1 (41.2, 76.4) | p < .001 |
| Step 3: Non-pneumatic anti-shock garment | |||
| Functional NASG in stock | 87.9 (63.3, 96.4) | 91.5 (66.7, 98.3) | p = .62 |
| Quantity of NASG in stock | |||
| None | 12.1 (3.6, 33.7) | 8.5 (1.7, 33.3) | p = .62 |
| 1–3 | 87.5 (66.3, 96.1) | 91.1 (67.2, 98.1) | |
| 4+ | 0.4 (0.2, 1.1) | 0.4 (0.2, 1.0) | |
